Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sites

▴ Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sites
The Bharat Biotech, which is into developing Covaxin - a vaccine candidate for COVID-19, on Friday said that it will now be conducting Phase III trials

The Bharat Biotech, which is into developing Covaxin - a vaccine candidate for COVID-19, on Friday said that it will now be conducting Phase III trials in 25 centres across the country with a total of 26,000 people participating in the trials. Bharat Biotech successfully completed interim analysis of Phase I and II trials of Covaxin. 

According to report, the Drug Controller General of India (DCGI) has also given Bharat Biotech the permission to go ahead with the Phase III trials after successful completion of Phase I and Phase II clinical trials.

"After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of Covaxin, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India," the vaccine maker said in an official communication.

An expert panel at the Central Drugs Standard Control Organisation (CDSCO) has recommended granting permission for conducting phase 3 clinical trials of its indigenously developed COVID-19 vaccine with certain conditions.

The phase 3 clinical trial application has proposed a dose of 0.5 ml on day 0 and 28.

Story Source- www.abplive.in 

Tags : #BharatBiotech #LatestNewsonBharatBiotech24thOct #LatestPharmaNews24thOct #LatestCOVIDNews24thOct #LatestNewsonCOVIDVaccine24thOct #DrugControllerGeneralofIndia

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Alembic Pharmaceuticals announces USFDA Final Approval for Metolazone TabletsDecember 03, 2020
QuEST Global provides COVID-19 support kits to more than 1,000 Police Officers in the cityDecember 03, 2020
Gujarat: Series of events mark ‘International Day of Persons with Disabilities’December 03, 2020
Number of COVID-19 positive cases rise in Mizoram, while COVID-19 recovery rate in Tripura improves December 03, 2020
IPC Statement On SARS-CoV-2 Vaccines And PsoriasisDecember 03, 2020
Roche receives USFDA emergency use authorization for new test to measure the level of SARS-CoV-2 antibodiesDecember 03, 2020
Country's COVID recovery rate reaches 94.11 per centDecember 03, 2020
Moderna CEO expects emergency use nod for COVID-19 vaccine after FDA panel meetDecember 03, 2020
Britain becomes first country in world to approve coronavirus vaccineDecember 03, 2020
Roche announces FDA approval of Gavreto for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancersDecember 03, 2020
Alembic Pharmaceuticals announces USFDA Final Approval for Metolazone Tablets USPDecember 03, 2020
Replacing red meat with plant foods may reduce the risk of heart diseaseDecember 03, 2020
Birth defects linked to greater risk of cancer in later lifeDecember 03, 2020
Combining telemedicine with AI will increase the productivity of clinicians and quality of care says Srinivas Prasad M R, Member, CII National Committee on Technology and R&DDecember 03, 2020
COVID is an opportunity to reshape the healthcare industry in India says Saurabh Bajpayee, Founder, Oxygenta HealthcareDecember 03, 2020
Second Covid wave expected to hit Karnataka in Jan-FebDecember 03, 2020
COVID19 cases: Maharashtra sees around 50% drop in November compared to October and SeptemberDecember 03, 2020
Moleculin announces FDA approval of 3 Rare pediatric disease designations for WP1066December 03, 2020
Health Decisions and OncoBay Clinical partners for development services in women's oncologyDecember 03, 2020
Impose Community service as penalty on those found violating COVID-19 safety norms: Gujarat High CourtDecember 03, 2020